155 related articles for article (PubMed ID: 36416257)
1. Biomimetic Nanovaccines Potentiating Dendritic Cell Internalization via CXCR4-Mediated Macropinocytosis.
Yang C; Zhang F; Chen F; Chang Z; Zhao Y; Shao D; Sun W; Dong WF; Wang Z
Adv Healthc Mater; 2023 Feb; 12(5):e2202064. PubMed ID: 36416257
[TBL] [Abstract][Full Text] [Related]
2. Engineering ApoE3-incorporated biomimetic nanoparticle for efficient vaccine delivery to dendritic cells via macropinocytosis to enhance cancer immunotherapy.
Zhou S; Huang Y; Chen Y; Liu S; Xu M; Jiang T; Song Q; Jiang G; Gu X; Gao X; Chen J
Biomaterials; 2020 Mar; 235():119795. PubMed ID: 32014739
[TBL] [Abstract][Full Text] [Related]
3. Leveraging β-Adrenergic Receptor Signaling Blockade for Improved Cancer Immunotherapy Through Biomimetic Nanovaccine.
Yang C; He Y; Chen F; Zhang F; Shao D; Wang Z
Small; 2023 Apr; 19(14):e2207029. PubMed ID: 36703529
[TBL] [Abstract][Full Text] [Related]
4. Engineering Polymeric Prodrug Nanoplatform for Vaccination Immunotherapy of Cancer.
Zhou L; Hou B; Wang D; Sun F; Song R; Shao Q; Wang H; Yu H; Li Y
Nano Lett; 2020 Jun; 20(6):4393-4402. PubMed ID: 32459969
[TBL] [Abstract][Full Text] [Related]
5. Antigen epitope-TLR7/8a conjugate as self-assembled carrier-free nanovaccine for personalized immunotherapy.
Song H; Su Q; Shi W; Huang P; Zhang C; Zhang C; Liu Q; Wang W
Acta Biomater; 2022 Mar; 141():398-407. PubMed ID: 35007785
[TBL] [Abstract][Full Text] [Related]
6. A Versatile and Robust Platform for the Scalable Manufacture of Biomimetic Nanovaccines.
Hu H; Yang C; Zhang F; Li M; Tu Z; Mu L; Dawulieti J; Lao YH; Xiao Z; Yan H; Sun W; Shao D; Leong KW
Adv Sci (Weinh); 2021 Aug; 8(15):2002020. PubMed ID: 34386315
[TBL] [Abstract][Full Text] [Related]
7. Self-adjuvant Astragalus polysaccharide-based nanovaccines for enhanced tumor immunotherapy: a novel delivery system candidate for tumor vaccines.
Li N; Zhang Y; Han M; Liu T; Wu J; Xiong Y; Fan Y; Ye F; Jin B; Zhang Y; Sun G; Sun X; Dong Z
Sci China Life Sci; 2024 Apr; 67(4):680-697. PubMed ID: 38206438
[TBL] [Abstract][Full Text] [Related]
8. Nanovaccine based on a protein-delivering dendrimer for effective antigen cross-presentation and cancer immunotherapy.
Xu J; Wang H; Xu L; Chao Y; Wang C; Han X; Dong Z; Chang H; Peng R; Cheng Y; Liu Z
Biomaterials; 2019 Jul; 207():1-9. PubMed ID: 30947117
[TBL] [Abstract][Full Text] [Related]
9. Engineered Nanovaccine Targeting Clec9a
Gou S; Liu W; Wang S; Chen G; Chen Z; Qiu L; Zhou X; Wu Y; Qi Y; Gao Y
Nano Lett; 2021 Dec; 21(23):9939-9950. PubMed ID: 34779631
[TBL] [Abstract][Full Text] [Related]
10. Intratumoral administration of STING-activating nanovaccine enhances T cell immunotherapy.
Jiang X; Wang J; Zheng X; Liu Z; Zhang X; Li Y; Wilhelm J; Cao J; Huang G; Zhang J; Sumer B; Lea J; Lu Z; Gao J; Luo M
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35623658
[TBL] [Abstract][Full Text] [Related]
11. Elastic Nanovaccine Enhances Dendritic Cell-Mediated Tumor Immunotherapy.
Li Q; Teng Z; Tao J; Shi W; Yang G; Zhang Y; Su X; Chen L; Xiu W; Yuwen L; Dong H; Mou Y
Small; 2022 Aug; 18(32):e2201108. PubMed ID: 35734820
[TBL] [Abstract][Full Text] [Related]
12. Toward Personalized Peptide-Based Cancer Nanovaccines: A Facile and Versatile Synthetic Approach.
Kakwere H; Ingham ES; Allen R; Mahakian LM; Tam SM; Zhang H; Silvestrini MT; Lewis JS; Ferrara KW
Bioconjug Chem; 2017 Nov; 28(11):2756-2771. PubMed ID: 28956907
[TBL] [Abstract][Full Text] [Related]
13. LncRNA-edited biomimetic nanovaccines combined with anti-TIM-3 for augmented immune checkpoint blockade immunotherapy.
Zhang Y; Liu F; Tan L; Li X; Dai Z; Cheng Q; Liu J; Wang Y; Huang L; Wang L; Wang Z
J Control Release; 2023 Sep; 361():671-680. PubMed ID: 37591462
[TBL] [Abstract][Full Text] [Related]
14. Biomimetic nanoparticles for DC vaccination: a versatile approach to boost cancer immunotherapy.
Meng L; Teng Z; Yang S; Wang N; Guan Y; Chen X; Liu Y
Nanoscale; 2023 Apr; 15(14):6432-6455. PubMed ID: 36916703
[TBL] [Abstract][Full Text] [Related]
15. RNA Origami Functions as a Self-Adjuvanted Nanovaccine Platform for Cancer Immunotherapy.
Yip T; Qi X; Yan H; Chang Y
ACS Nano; 2024 Feb; 18(5):4056-4067. PubMed ID: 38270089
[TBL] [Abstract][Full Text] [Related]
16. Therapy of established tumour with a hybrid cellular vaccine generated by using granulocyte-macrophage colony-stimulating factor genetically modified dendritic cells.
Cao X; Zhang W; Wang J; Zhang M; Huang X; Hamada H; Chen W
Immunology; 1999 Aug; 97(4):616-25. PubMed ID: 10457215
[TBL] [Abstract][Full Text] [Related]
17. Minimalist Nanovaccine with Optimized Amphiphilic Copolymers for Cancer Immunotherapy.
Niu L; Miao Y; Cao Z; Wei T; Zhu J; Li M; Bai B; Chen L; Liu N; Pan F; Zhu J; Wang C; Yang Y; Chen Q
ACS Nano; 2024 Jan; 18(4):3349-3361. PubMed ID: 38230639
[TBL] [Abstract][Full Text] [Related]
18. Liposomes-coated gold nanocages with antigens and adjuvants targeted delivery to dendritic cells for enhancing antitumor immune response.
Liang R; Xie J; Li J; Wang K; Liu L; Gao Y; Hussain M; Shen G; Zhu J; Tao J
Biomaterials; 2017 Dec; 149():41-50. PubMed ID: 28992509
[TBL] [Abstract][Full Text] [Related]
19. Mimetic Heat Shock Protein Mediated Immune Process to Enhance Cancer Immunotherapy.
Li X; Cai X; Zhang Z; Ding Y; Ma R; Huang F; Liu Y; Liu J; Shi L
Nano Lett; 2020 Jun; 20(6):4454-4463. PubMed ID: 32401534
[TBL] [Abstract][Full Text] [Related]
20. CXCR4-Targeted Macrophage-Derived Biomimetic Hybrid Vesicle Nanoplatform for Enhanced Cancer Therapy through Codelivery of Manganese and Doxorubicin.
Jang Y; Cho YS; Kim A; Zhou X; Kim Y; Wan Z; Moon JJ; Park H
ACS Appl Mater Interfaces; 2024 Apr; 16(14):17129-17144. PubMed ID: 38533538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
